## **SUPPLEMENTARY MATERIAL**

Supplementary Methods: Assessment of cardiovascular health

Table S1: Baseline categories of income and education

Table S2: Definition of Life's Simple 7 Metrics

Table S3: Distribution of Life's Simple 7 Metrics by Sex

Table S4: The associations between CVH score and CVD-related biomarkers by

Race/Ethnicity for Women

Table S5: The associations between CVH score and CVD-related biomarkers by

Race/Ethnicity for Men

Table S6: The associations between CVH score and CVD-related biomarkers by Age

for Women

Table S7: The associations between CVH score and CVD-related biomarkers by Age

for Men

## **Supplementary Methods: Assessment of cardiovascular health**

Information on the LS7 metrics were collected from study participants at baseline. Based on AHA guidelines, ideal CVH is achieved if the following criteria are met for the LS7 metrics: non-smoking, physical activity at goal levels, BMI <25kg/m² and a healthy diet consistent with guidelines, total cholesterol <200mg/dL (not on lipid lowering medications), blood pressure <120/<80mmHg (not on anti-hypertensive medications), and fasting blood glucose <100mg/dL (not on diabetes medications) <sup>1</sup>. Smoking status was assessed by self-report and categorized as; 1) participants who never smoked or quit more than 12 months (non-smokers), 2) participants who quit within 12 months (former smokers) and 3) current smokers <sup>1</sup>. Physical activity was evaluated using a self-report survey instrument adapted from the Cross-Cultural Activity Participation Study <sup>2</sup> containing 28 questions on time and frequency of activities during a week in the previous month. The total minutes of moderate and vigorous exercise in metabolic equivalents of task (MET/min) were estimated and used for our analyses <sup>3</sup>.

BMI (kg/m²) was calculated using the weight and height measurements. Dietary habits were evaluated using a 120-item validated food frequency questionnaire modified from the Insulin Resistance Atherosclerosis Study instrument <sup>4, 5</sup>. Based on recommended dietary guidelines, a healthy diet was made up of fruits and vegetables, fish, whole grains and intake of sodium <1500mg per day and sugar-sweetened beverages ≤450 kcal (36 oz.) per week <sup>1</sup>. For blood pressure, with participants in a seated position, 3 measurements were obtained after resting for 5 minutes and the average values of the last two readings were recorded. For total cholesterol (mg/dL)

and blood glucose (mg/dL) measurements, blood samples were collected following a 12 hour fast.

	Income			Education					
1	< \$5,000	131 (2%)	1	NO SCHOOLING	60 (1%)				
2	\$5,000-\$7,999	214 (4%)	2	GRADES 1-8	558 (10%)				
3	\$8,000-\$11,999	310 (6%)	3	GRADES 9-11	367 (7%)				
4	\$12,000-\$15,999	399 (7%)	4	COMPLETED HIGH SCHOOL/GED	950 (18%)				
5	\$16,000-\$19,999	275 (5%)	5	SOME COLLEGE BUT NO DEGREE	855 (16%)				
6	\$20,000-\$24,999	404 (8%)	6	TECHNICAL SCHOOL CERTIFICATE	385 (7%)				
7	\$25,000-\$29,999	311 (6%)	7	ASSOCIATE DEGREE	275 (5%)				
8	\$30,000-\$34,999	374 (7%)	8	BACHELOR'S DEGREE	951 (18%)				
9	\$35,000-\$39,999	313 (6%)	9	GRADUATE OR PROFESSIONAL SCHOOL	978 (18%)				
10	\$40,000-\$49,999	517 (10%)							
11	\$50,000-\$74,999	883 (16%)							
12	\$75,000-\$99,999	483 (9%)							
13	\$100,000+	765 (14%)							

Table S2 – Definition of the Life's Simple 7 metrics									
LS7 Metrics	Score	Definition							
Smoking	0	Current smoker							
	1	Former smoker, quit ≤12 months ago							
	2	Never smoker or quit >12 months ago							
Body Mass Index	0	≥30 kg/m²							
	1	25.0-29.99 kg/m <sup>2</sup>							
	2	<25.0 kg/m <sup>2</sup>							
Physical Activity	0	Current smoker Former smoker, quit ≤12 months ago Never smoker or quit >12 months ago ≥30 kg/m² 25.0–29.99 kg/m² <25.0 kg/m² No exercise 1–149 min of moderate exercise or 1–74 min vigorous exercise/week 150+ min of moderate exercise or 75+ min or vigorous exercise/week 0–1 components of healthy diet 2–3 components of healthy diet 4–5 components of healthy diet 4–5 components of healthy diet ≥240 mg/dL 200–239 mg/dL or treated to <200mg/dL <200 mg/dL, unmedicated SBP ≥140 mmHg or DBP ≥90 mmHg SBP 120–139 mmHg or DBP 80–89 mmHg of treated to <120/80 mm Hg <120/80 mm Hg, unmedicated ≥126 mg/dL fasting 100–125 mg/dL fasting or treated to <100							
	1	No exercise 1–149 min of moderate exercise or 1–74 min vigorous exercise/week 150+ min of moderate exercise or 75+ min o vigorous exercise/week							
		vigorous exercise/week							
	2	150+ min of moderate exercise or 75+ min of							
		vigorous exercise/week							
Diet	0	0-1 components of healthy diet							
	1	2–3 components of healthy diet							
	2	4–5 components of healthy diet							
Total Cholesterol	0	150+ min of moderate exercise or 75+ min of vigorous exercise/week  0-1 components of healthy diet 2-3 components of healthy diet 4-5 components of healthy diet ≥240 mg/dL  200-239 mg/dL or treated to <200mg/dL <200 mg/dL, unmedicated							
	1	200-239 mg/dL or treated to <200mg/dL							
	2	<200 mg/dL, unmedicated							
Blood Pressure	0	SBP ≥140 mmHg or DBP ≥90 mmHg							
	1	SBP 120–139 mmHg or DBP 80–89 mmHg or							
		treated to <120/80 mm Hg							
	2								
Blood Glucose	0								
	1	100-125 mg/dL fasting or treated to <100							
		mg/dL							
	2	<100 mg/dL fasting, unmedicated							

Adapted from Lloyd Jones et al<sup>1</sup> and Unger et al<sup>3</sup>, LS7 indicates Life's Simple 7; DBP, diastolic blood pressure, and SBP, systolic blood pressure. Poor=0 points; Intermediate=1 point; ideal =2 points. \*When combining vigorous and moderate exercise, vigorous exercise was weighted double.

Table S3 - Distribution of Life's Simple 7 Metrics by Sex								
	Total (N=5,379)	Women (n= 2,775)	Men (n= 2,604)	P value				
Total CVH score, mean (SD)	8.6 (2.2)	8.6 (2.3)	8.6 (2.1)	0.85				
LS7 metrics, n (%)								
Smoking								
Poor	671 (12)	303 (11)	368 (14)					
Intermediate	68 (1) <sup>′</sup>	27 (1)	41 (2)	< 0.001				
Ideal	4640 (86)	2445 (88)	2195 (84)					
Body mass index	` ,	•	, ,					
Poor	1657 (31)	958 (35)	699 (27)					
Intermediate	2127 (40)	936 (34)	1191 (46)	< 0.001				
Ideal	1595 (30)	881 (32)	714 (28)					
Physical activity	` ,	, ,	, ,					
Poor	1231 (23)	684 (25)	547 (21)					
Intermediate	909 (17)	529 (19)	380 (15)	< 0.001				
Ideal	3239 (6Ó)	1562 (56)	1677 (64)					
Diet	,	, , , , , , , , , , , , , , , , , , ,						
Poor	2425 (45)	1029 (37)	1396 (54)					
Intermediate	2898 (54)	1699 (61)	1199 (46)	< 0.001				
Ideal	56 (Ì) ´	47 (2)	9 (0.4)					
Total Cholesterol	. ,	. ,	· /					
Poor	729 (14)	466 (17)	263 (10)					
Intermediate	2107 (39)	1143 (41)	964 (37)	< 0.001				
Ideal	2543 (47)	1166 (42)	1377 (53)					
Blood pressure	,	, , , , , , , , , , , , , , , , , , ,						
Poor	1996 (37)	1085 (39)	911 (35)					
Intermediate	1505 (28)	695 (25) <sup>′</sup>	810 (̀31)́	< 0.001				
Ideal	1878 (35)	995 (36)	883 (34)					
Blood glucose	, ,	, ,	, ,					
Poor	572 (11)	275 (10)	297 (11)					
Intermediate	846 (16)	359 (13)	487 (19)	< 0.001				
Ideal	3961 (74)	2141 (77)	1820 (70)					

Abbreviations: CVH indicates cardiovascular health; SD, standard deviation; LS7, Life's Simple 7; percentages were rounded up to whole numbers

	Table S4 - The	associations betw	ween CVH score a	and CVD-related bi	omarkers by Race/	Ethnicity for Wom	en
	hsCRP	D-dimer	Fibrinogen	Homocysteine	hs-cTnT	NT-ProBNP	IL-6 <sup>†</sup>
	(mg/L)	(µg/mL)	(mg/dL)	(µmol/L)	(ng/L)	(pg/mL)	(pg/mL)
White, n=1,0	092						
Model 1	-0.18	-0.06	-0.03	-0.02	-0.05	0.01	-0.10
	(-0.21, -0.15)	(-0.08, -0.04)	(-0.04, -0.03)	(-0.03, -0.01)	(-0.06, -0.04)	(-0.01, 0.04)	(-0.12, -0.08)
Model 2	-0.19	-0.04	-0.03	-0.01	-0.03	0.05	-0.09
	(-0.23,-0.16)	(-0.07, -0.02)	(-0.04, -0.02)	(-0.02, -0.002)	(-0.04, -0.02)	(0.03, 0.07)	(-0.11, -0.07)
Chinese-An	nerican, n=372						
Model 1	-0.11	-0.08	-0.02	-0.03	-0.05	-0.01	-0.07
	(-0.17, -0.06)	(-0.13, -0.04)	(-0.02, -0.01)	(-0.04, -0.02)	(-0.07, -0.03)	(-0.06, 0.05)	(-0.10, -0.04)
Model 2	-0.13	-0.04	-0.01	-0.01	-0.03	0.07	-0.06
	(-0.18, -0.07)	(-0.09, 0.01)	(-0.02, -0.004)	(-0.03, -0.00)	(-0.005, -0.01)	(0.02, 0.12)	(-0.10, -0.03)
Black, n=68	1						
Model 1	-0.15	-0.06	-0.03	-0.02	-0.04	-0.02	-0.09
	(-0.19, -0.11)	(-0.09, -0.03)	(-0.03, -0.02)	(-0.03, -0.01)	(-0.06, -0.02)	(-0.06, 0.02)	(-0.11, -0.07)
Model 2	-0.15	-0.05	-0.02	-0.01	-0.03	0.005	-0.08
	(-0.19, -0.10)	(-0.08, -0.02)	(-0.03, -0.02)	(-0.02, -0.004)	(-0.05, -0.01)	(-0.03, 0.04)	(-0.11, -0.06)
Hispanic, n	= 630						
Model 1	-0.13	-0.03	-0.01	-0.02	-0.04	-0.04	-0.09
	(-0.17, -0.10)	(-0.07, -0.003)	(-0.02, -0.01)	(-0.03, -0.01)	(-0.05, -0.02)	(-0.07, -0.003)	(-0.11, -0.07)
Model 2	-0.14	-0.004	-0.01	-0.01	-0.02	0.01	-0.08
	(-0.18, -0.10)	(-0.04, 0.03)	(-0.02, -0.005)	(-0.02, -0.002)	(-0.04, -0.005)	(-0.03, 0.04)	(-0.10, -0.06)

Abbreviations: CVH, cardiovascular health; CVD, cardiovascular disease; hsCRP; High-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-ProBNP, N-terminal pro B-type natriuretic peptide; IL-6, interleukin 6.

<sup>\*</sup>All biomarkers were log-transformed; CVH was assessed as a continuous variable. Results are presented as beta-coefficients (95% CI) from multivariable adjusted linear regression. Model 1 was unadjusted; Model 2 was adjusted for age, education, income, and health insurance status. Interpretation: For example, a 1-unit increment in the CVH score in White women corresponds to a 0.18 mg/L lower logCRP concentration. † For IL-6, Women: White, n=1,080; Chinese-American, n=371; Black, n=664; Hispanic, n=618

	hsCRP	D-dimer	Fibrinogen	Homocysteine	hs-cTnT	NT-ProBNP	IL-6 <sup>†</sup>
	(mg/L)	(µg/mL)	(mg/dL)	(µmol/L)	(ng/L)	(pg/mL)	(pg/mL)
White, n=1,05	8						
Model 1	-0.15	-0.02	-0.02	-0.02	-0.04	0.002	-0.08
	(-0.18, -0.12)	(-0.05, 0.004)	(-0.02, -0.01)	(-0.02, -0.01)	(-0.06, -0.02)	(-0.03,0.03)	(-0.10,-0.06)
Model 2	-0.14	-0.02	-0.02	-0.02	-0.04	0.01	-0.07
	(-0.17, -0.11)	(-0.05, 0.005)	(-0.02, -0.01)	(-0.02, -0.01)	(-0.06, -0.03)	(-0.02, 0.04)	(-0.09, -0.05)
Chinese-Ame	rican, n= 361						
Model 1	-0.09	-0.01	-0.01	-0.02	-0.06	0.04	-0.04
	(-0.15, -0.04)	(-0.06, 0.04)	(-0.02, -0.01)	(-0.03, -0.001)	(-0.08, -0.03)	(-0.02, 0.11)	(-0.07, 0.0002)
Model 2	-0.11	0.001	-0.02	-0.02	-0.06	0.02	-0.03
	(-0.17, -0.05)	(-0.05, 0.05)	(-0.03, -0.01)	(-0.03, -0.002)	(-0.09, -0.04)	(-0.03, 0.07)	(-0.07, 0.004)
Black, n= 572							
Model 1	-0.07	-0.05	-0.02	-0.01	-0.09	-0.03	-0.04
	(-0.12, -0.03)	(-0.09, -0.01)	(-0.03, -0.01)	(-0.02, -0.001)	(-0.11, -0.06)	(-0.08, 0.02)	(-0.07, -0.02)
Model 2	-0.06	-0.02	-0.01	-0.01	-0.07	0.02	-0.03
	(-0.11, -0.02)	(-0.06, 0.01)	(-0.02, -0.01)	(-0.02, 0.003)	(-0.09, -0.05)	(-0.03, 0.06)	(-0.06, -0.01)
Hispanic, n=6	13						
Model 1	-0.08	-0.03	-0.02	-0.001	-0.08	-0.06	-0.06
	(-0.12, -0.04)	(-0.06, 0.01)	(-0.03, -0.01)	(-0.01, 0.01)	(-0.11, -0.06)	(-0.11, -0.01)	( -0.08, -0.03)
Model 2	-0.08	-0.01	-0.02	0.003	-0.08	-0.03	-0.05
	(-0.12, -0.04)	(-0.04, 0.02)	(-0.02, -0.01)	(-0.01, 0.01)	(-0.10, -0.05)	(-0.07, 0.02)	(-0.07, -0.02)

Abbreviations: CVH, cardiovascular health; CVD, cardiovascular disease; hsCRP; High-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide; IL-6, interleukin 6.

<sup>\*</sup>All biomarkers were log-transformed; CVH was assessed as a continuous variable. Results are presented as beta-coefficients (95% CI) from multivariable adjusted linear regression. Model 1 was unadjusted; Model 2 was adjusted for age, education, income, and health insurance status. Interpretation: For example, a 1-unit increment in the CVH score in White men corresponds to a 0.15mg/L lower logCRP concentration. † For IL-6, Men: White, n=1,042; Chinese American, n=355; Black, n=554; Hispanic, n=595

	hsCRP (mg/L)	D-dimer (µg/mL)	etween CVH sco Fibrinogen (mg/dL)	Homocysteine (µmol/L)	hs-cTnT (ng/L)	NT-proBNP (pg/mL)	IL-6† (pg/mL)
Age <65 years, r	n=1,559						
Model 1	-0.22	-0.07	-0.03	-0.02	-0.03	0.03	-0.11
	(0.24, -0.19)	(-0.09, -0.05)	(-0.04, -0.03)	(-0.02, -0.01)	(-0.03, -0.02)	(0.01, 0.06)	(-0.13, -0.10)
Model 2	-0.19	-0.04	-0.03	-0.01	-0.02	0.03	-0.09
	(-0.21, -0.16)	(-0.06, -0.02)	(-0.03, -0.02)	(-0.02, -0.01)	(-0.03, -0.01)	(0.004, 0.05)	(-0.10, -0.07)
Age ≥ 65 years,	n= 1,216						
Model 1	-0.14	-0.06	-0.02	-0.02	-0.05	0.02	-0.09
	(-0.17, -0.11)	(-0.08, -0.04)	(-0.03, -0.02)	(-0.02, -0.01)	(-0.07, -0.04)	(-0.01, 0.04)	(-0.11, -0.07)
Model 2	-0.12	-0.03	-0.02	-0.01	-0.05	0.01	-0.07
	(-0.15, -0.09)	(-0.06, -0.01)	(-0.02, -0.01)	(-0.02, -0.01)	(-0.06, -0.03)	(-0.02, 0.03)	(-0.09, -0.06

Abbreviations: CVH, cardiovascular health; CVD, cardiovascular disease; hsCRP; High-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide; IL-6, interleukin 6.

<sup>\*</sup>All biomarkers were log-transformed; CVH was assessed as a continuous variable. Results are presented as beta-coefficients (95% CI) from multivariable adjusted linear regression. Model 1 was unadjusted; Model 2 was adjusted for race/ethnicity, education, income, and health insurance status. Interpretation: For example, a 1-unit increment in the CVH score in women <65 years corresponds to a 0.22mg/L lower logCRP concentration. † For IL-6, Women: Age <65, n=1,539 Age ≥ 65 years, n=1,194

	hsCRP	D-dimer	Fibrinogen	Homocysteine	hs-cTnT	NT-proBNP	IL-6†
	(mg/L)	(µg/mL)	(mg/dL)	(µmol/L)	(ng/L)	(pg/mL)	(pg/mL)
Age <65 years	s, n= 1,454						
Model 1	-0.14	-0.02	-0.02	-0.01	-0.07	-0.02	-0.07
	(-0.17, -0.12)	(-0.05, -0.003)	(-0.03, -0.02)	(-0.01, -0.001)	(-0.08, -0.06)	(-0.04, 0.01)	(-0.09, -0.06)
Model 2	-0.12	-0.02	-0.02	-0.01	-0.07	-0.01	-0.06
	(-0.15, -0.10)	(-0.04, 0.007)	(-0.02, -0.01)	(-0.01, -0.00)	(-0.08, -0.05)	(-0.04, 0.02)	(-0.08, -0.04)
Age ≥ 65 year	s, n= 1,150						
Model 1	-0.11	-0.05	-0.02	-0.02	-0.06	0.01	-0.06
	(-0.14, -0.08)	(-0.07, -0.02)	(-0.02, -0.01)	(-0.02, -0.01)	(-0.08, -0.04)	(-0.02, 0.04)	(-0.08, -0.04)
Model 2	-0.07	-0.03	-0.01	-0.02	-0.05	0.01	-0.04
	(-0.10, -0.04)	(-0.05, -0.001)	(-0.02, -0.01)	(-0.02, -0.01)	(-0.07, -0.03)	(-0.02, 0.05)	(-0.06, -0.02)

Abbreviations: CVH, cardiovascular health; CVD, cardiovascular disease; hsCRP; High-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide; IL-6, interleukin 6.

\*All biomarkers were log-transformed; CVH was assessed as a continuous variable. Results are presented as beta-coefficients (95% CI) from

<sup>\*</sup>All biomarkers were log-transformed; CVH was assessed as a continuous variable. Results are presented as beta-coefficients (95% CI) from multivariable adjusted linear regression. Model 1 was unadjusted; Model 2 was adjusted for race/ethnicity, education, income, and health insurance status. Interpretation: For example, a 1-unit increment in the CVH score in men <65 years corresponds to a 0.14mg/L lower logCRP concentration. † For IL-6, Men: Age <65, n=1,425; Age ≥ 65 years, n=1,121

## **References for Supplementary Material**

- 1. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation* 2010; **121**:586-613.
- 2. Ainsworth BE, Irwin ML, Addy CL, et al. Moderate physical activity patterns of minority women: the Cross-Cultural Activity Participation Study. *J Womens Health Gend Based Med* 1999; **8**:805-13.
- 3. Unger E, Diez-Roux AV, Lloyd-Jones DM, et al. Association of neighborhood characteristics with cardiovascular health in the multi-ethnic study of atherosclerosis. *Circ Cardiovasc Qual Outcomes* 2014; **7**:524-31.
- 4. Block G, Woods M, Potosky A, et al. Validation of a self-administered diet history questionnaire using multiple diet records. *J Clinical Epidemiol* 1990; **43**:1327-35.
- 5. Mayer-Davis EJ, Vitolins MZ, Carmichael SL, et al. Validity and reproducibility of a food frequency interview in a Multi-Cultural Epidemiology Study. *Ann Epidemiol* 1999; **9**:314-24.